Performance Data

Performance Data

Below are key performance indicators (KPIs) for each of our four focus areas (Access to Health, Employees, Environmental Sustainability, and Ethics & Transparency), as well as links to the performance data tables found throughout this site.

Resources

 

These KPIs serve as baseline measurements for our corporate responsibility activities, are measured globally unless otherwise noted, and cover all of our business units with the exception of joint ventures.

Access to Health

Key Performance Indicators (KPIs)

Research & Development2013 2014 2015 2016 2017
Top 20 global burdens of disease addressed by our products and pipeline288% 88% 88% 88% 88%
GCP/PV audits by regulatory agencies or clinical trial investigators that led to significant fines, penalties, warning letters or product seizures1 - 0 0 - 0
Established significant external licenses and collaborations340 35 64 57 55
Narrative of compounds provided to product-development partnerships4 Online
Manufacturing & Supply2013 2014 2015 2016 2017
Annual percentage of units manufactured/sold and recalled during a given year (recall rate globally)5, 60.11% 0.22% 0.07% 0.01% 0.01%
Number of local and regional manufacturing partnerships to enable access68 104 179 179 153
Number of products available by local and regional partnerships7354 499 1,157 941 765
Registration2013 2014 2015 2016 2017
New product and device registrations8, 9, 10179 176 156 143 143
Local regulatory agency GCP/PV training requests fulfilled that will help strengthen agency capabilities with their GCP/PV compliance oversight role11 Link
Products submitted that have achieved WHO prequalification11 11 11 11 13
Pricing & Commercialization2013 2014 2015 2016 2017
Number of products which are supported with differential pricing12, 1324 35 35 40 42
Number of countries where inter- and/or intra-country pricing has been implemented1470 114 121 123 125
Investment in patient- and provider-education programs (in millions)$61$52$80$80$90
Community Investment2013 2014 2015 2016 2017
Health care workers trained through major programs and partnerships1522,000 137,000 19,000 32,000 74,000
Investment in partnerships for activities to address underlying barriers to health, such as health-system strengthening and capacity building (in millions)15$24 $32 $21 $28 $40
People reached through major programs & partnerships (in millions)15302 267 188 293 311
Community Investment2013 2014 2015 2016 2017
Health care workers trained through major programs and partnerships1522,000 137,000 19,000 32,000 74,000
Investment in partnerships for activities to address underlying barriers to health, such as health-system strengthening and capacity building (in millions)15$24 $32 $21 $28 $40
People reached through major programs & partnerships (in millions)15302 267 188 293 311
NA: Not available.
Note: Unless otherwise stated, data for Access to Health are reflective of our Human Health business only; information on our company's Animal Health is reported separately.
1. Complete response letter received for Sugammadex (MK-8616) in 2013, and the complete response letter received for Januvia (sitagliptin; MK-0431) in 2016.
2. As defined by the Institute for Health Metrics and Evaluation (IHME), which replaces the previously used WHO chart of leading causes of disease, condition or injury.
3. Starting in 2014, this metric no longer includes select early licenses and research collaborations that were included in the metric for previous years.
4. For information on product-development partnerships, visit our Research & Development page.
5. Definition of Recall Classifications: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm049070.htm#RecallClassifications.
6. Starting in 2014, product recalls include data from our Animal Health business.
7. Increase represented in 2015 is due in part by better visibility to global partner information.
8. Data includes new products and new indications.
9. For information on new registrations by region, visit our Clinical Research section.
10. Data for all years have been updated based on a tracking system upgrade that corrected miscounts in prior years.
11. For information on local regulatory agency GCP/PV training requests, visit our Clinical Research section.
12. Differential pricing intended to facilitate access for the at-need population.
13. Products include HIV treatments, vaccines and other patented products.
14. Countries as defined by the World Bank 2017 GNI Classification, including UN-defined Least Developed Countries.
15. Includes investments by the Office of Corporate Responsibility, MSD for Mothers and/or our company's Foundation.

Employees

Key Performance Indicators (KPIs)

Diversity & Inclusion2013 2014 2015 2016 2017
Women in executive roles131% 31% 34% 31% 32%
Women on the Board 17% 17% 21% 23% 23%
Members of underrepresented ethnic groups on the Board25% 25% 21% 23% 23%
Members of underrepresented ethnic groups in executive roles (U.S.) 20% 20% 20% 23% 23%
Members of underrepresented ethnic groups in the workforce (U.S.)24% 24% 26% 26% 26%
Well-Being2013 2014 2015 2016 2017
Response rate to the Voice Survey77% 78% NA 85% NA
Employees who completed a health assessment (U.S.)62% 57% 58% 57% 70%
Lost-time incident rate (LTIR)0.28 0.20 0.22 0.13 0.13
Recordable injury rate (RIR)0.62 0.58 0.48 0.35 0.33
Volunteerism2013 2014 2015 2016 2017
Employees who took release time according to the global policy on employee volunteerism2NA 12.5% 9.0% 21.0 % 7.0%
Total recorded volunteer hours3NA 109,932 80,585 214,862 114,903
NA: Not available.
1. “Executive” is defined as the chief executive officer and two structural levels below.
2. Where specific data is not available, data has been estimated.
3. 2017 figures are based on employee self-recorded volunteer hours and volunteer hours communicated directly to the Office of Corporate Responsibility for certain countries. 2015 marked the first year in which volunteer hour reporting was based solely on employee self-reporting. Prior years included estimates for unrecorded volunteer hours.

Environmental Sustainability

Key Performance Indicators (KPIs)1

2013 2014 2015 2016 2017
Greenhouse gas emissions (Scope 1 & 2) (MT CO2e)21,639,700 1,530,800 1,456,100 1,398,100 1,264,100
Water usage (m3)28.4 26.9 23.9 20.6 19.5
Operational waste generated (MT)96,256 83,732 69,856 72,599 72,426
1. Includes facilities worldwide.
2. In accordance with the Greenhouse Gas Protocol, prior-year data have been adjusted to add or remove facilities that have been acquired or sold. Adjustments also reflect changes in methodology to ensure consistency from year to year.

Ethics & Transparency

Key Performance Indicators (KPIs)

2013 2014 2015 2016 2017
Employees trained on our Code of Conduct99% 99% 99% 100% 100%
Ratio of substantiated allegations to concerns/issues raised 58% 60% 58% 55% 60%
Reported concerns that were substantiated regarding privacy practices, breaches of privacy and losses of personal data and devices.1, 226% 18% 96% 98% 98%
1. Privacy concerns include all concerns escalated to our Privacy Office about the company’s privacy practices. Substantiated concerns are those that are determined to be inconsistent with our privacy standards or that involve the loss of, theft of or unauthorized access to personal data.
2. In 2015, because of the scope of lost or stolen devices known to be encrypted, we ceased inclusion of lost or stolen MSD devices in our incident metrics.

Economic Impact